Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Details
Serval ID
serval:BIB_9DE759B0F4B3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Journal
Osteoporosis International
Contributor(s)
HORIZON Pivotal Fracture Trial, Black D., Cummings S., Delmas P., Eastell R., Reid I., Boonen S., Cauley J., Cosman F., Lakatos P., Leung PC., Man Z., Eriksen EF., Mesenbrink P., Lau E., Jasqui S., Mautalen C., Rosario-Jansen T., Caminis J., Raisz L., Bauer P., Compston J., DeMets D., Hirschberg R., Johnell O., Ralston S., Wallace R., Farkough M., Flood M., Bauer D., Palermo L., Lang T., Kerzberg E., Man Z., Mautalen C., Rosario-Jansen T., Caminis J., Raisz L., Bauer P., Compston J., DeMets D., Hirschberg R., Johnell O., Ralston S., Wallace R., Farkough M., Flood M., Bauer D., Palermo L., Lang T., Kerzberg E., Man Z., Mautalen C., Ridruejo M., Tate G., Velasco J., Hooper M., Kotowicz M., Nash P., Prince R., Roberts A., Sambrook P., Dobnig H., Finkenstedt G., Hoefle G., Klaushofer K., Pecherstorfer M., Peichl P., Body J., Boonen S., Devogelaer JP., Geusens P., Kaufman J., Brenol£££João£££ J. , Kochen J., Lederman R., Radominski S., Szejnfeld V., Zerbini C., Adachi J., Brown J., Choquette D., Hanley D., Josse R., Kendler D., Kremer R., Morin F., Olszynski W., Papaioannou A., KinYuen C., Chen B., Lin S., Casas N., Chalem M., Jaller J., Molina J., Aro H., Heikkinen J., Kröger H., Mäkinen L., Saltevo J., Salmi J., Välimäki M., Benhamou CL., Delmas P., Fardellone P., Werhya G., Allolio B., Felsenberg D., Happ J., Hartard M., Hensen J., Kaps P., Kekow J., Moericke R., Ortloff B., Schneider P., Wassenberg S., Leung PC., Balogh A., Gomor B., Hidvégi T., Koranyi L., Lakatos P., Poór G., Zsolt T., Pollak RD., Eshed V., Foldes AJ., Ish-Shalom S., Vered I., Weiss M., Adami S., Barone A., Bianchi G., Giannini S., Isaia GC., Luisetto G., Minisola S., Molea N., Nuti R., Ortolani S., Passeri M., Rubinacci A., Seriolo B., Sinigaglia L., Choi WH., Kang MI., Kim GS., Kim HS., Kim YK., Lim SK., Son HY., Yoon HK., Abud C., Garcia P., Jasqui S., Ochoa L., Orozco J., Santos J., Reid I., Elle£££Sigbjørn£££ S. , Halse J., Høiseth A., Olav H., Røed£££Høivik Ingun£££ HI. , Skag A., Stakkestad J., Syversen U., Badurski J., Czerwinski E., Lorenc R., Marcinowska-Suchowierska E., Sawicki A., Supronik J., Ailamazyan E., Benevolenskaya L., Dreval A., Dvoretsky L., Dyomina R., Mazurov V., Melnichenko G., Mkrtoumyan A., Orlov-Morozov A., Ostroumova O., Pikhlak E., Shemerovskaya T., Shostak N., Skripnikova I., Smetnik V., Tsyrlina E., Usova G., Zalevskaya A., Zazerskaya I., Zotkin E., Ljunggren O., Lofgren J., Palmér M., Saaf M., Stenström M., Hasler P., Lamy O., Lippuner K., Merlin C., Rizzoli R., Theiler R., Tyndall A., Uebelhart D., Chen JF., Chen PQ., Chin LS., Hwang JS., Yang TS., Jirapinyo M., Jirapinyo M., Sattaya R., Sriussadaporn S., Supasin S., Taechakraichana N., Wilawan K., Donnachie H., Eastell R., Fraser W., McLellan A., Reid D., Abruzzo J., Ackerman R., Adler R., Aloia J., Birbara C., Bode B., Bone H., Brandon D., Cauley J., Cosman F., Dionne D., Downs R.<Suffix>Jr</Suffix> , Dreyfus J., Elinoff V., Emkey R., Fanciullo J., Fiske D., Genaro P., Gollapudi M., Gordon R., Hennessey J., Howard P., Johnson K., Johnston C., Kagan R., Kafka S., Kaine J., Klein T., Koltun W., Leboff M., Levine B., Lewiecki EM., Lewis CE., Licata A., Lillestol M., Lubin B., Malamet R., Mangione A., Matkovic V., Mehta D., Miller P., Miller S., Murphy FT., Nattrass S., Podlecki D., Recknor C., Rosen C., Rowe D., Rude R., Schnitzer T., Sherrer Y., Silverman S., Stephenson K., Troupin B., Tucci J., Villareal R., Watts N., Weinstein R., Weinstein R., Weitz M., White R.
ISSN
1433-2965 (Electronic)
ISSN-L
0937-941X
Publication state
Published
Issued date
2010
Volume
21
Number
7
Pages
1277-1285
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength.
INTRODUCTION: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength.
METHODS: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated.
RESULTS: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001).
CONCLUSIONS: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.
INTRODUCTION: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength.
METHODS: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated.
RESULTS: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001).
CONCLUSIONS: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.
Keywords
Absorptiometry, Photon/methods, Aged, Aged, 80 and over, Bone Density/drug effects, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/therapeutic use, Compressive Strength/drug effects, Diphosphonates/administration & dosage, Diphosphonates/therapeutic use, Drug Administration Schedule, Female, Femur Neck/drug effects, Femur Neck/physiopathology, Follow-Up Studies, Hip Joint/drug effects, Hip Joint/physiopathology, Humans, Imidazoles/administration & dosage, Imidazoles/therapeutic use, Lumbar Vertebrae/drug effects, Lumbar Vertebrae/physiopathology, Osteoporosis, Postmenopausal/drug therapy, Osteoporosis, Postmenopausal/physiopathology, Tomography, X-Ray Computed/methods
Pubmed
Web of science
Create date
22/02/2011 15:57
Last modification date
20/08/2019 16:04
Usage data
